These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35879722)

  • 41. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
    Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
    Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Twenty Fraction Prostate Radiotherapy with Intra-prostatic Boost: Results of a Pilot Study.
    Onjukka E; Uzan J; Baker C; Howard L; Nahum A; Syndikus I
    Clin Oncol (R Coll Radiol); 2017 Jan; 29(1):6-14. PubMed ID: 27692920
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.
    Thor M; Deasy JO; Paulus R; Robert Lee W; Amin MB; Bruner DW; Low DA; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Gore EM; Albert M; Pisansky TM; Faria SL; Chen Y; Koontz BF; Swanson GP; Pugh SL; Sandler HM
    Radiother Oncol; 2019 Jun; 135():19-24. PubMed ID: 31015166
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biological effective dose in analysis of rectal dose in prostate cancer patients who underwent a combination therapy of VMAT and LDR with hydrogel spacer insertion.
    Zhang H; Wang L; Riegel AC; Antone J; Potters L; Lee L; Cao Y
    J Appl Clin Med Phys; 2022 Jun; 23(6):e13584. PubMed ID: 35285578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rectal sparing in prostate radiotherapy with combination-brachytherapy and hydrogel spacer.
    Cousins MM; Heckman P; Short E; Narayana V; Bryant AK; Evans C; Hixson G; Hurley P; McLaughlin PW
    Brachytherapy; 2022; 21(3):300-307. PubMed ID: 35125329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy.
    McDonald AM; Baker CB; Popple RA; Shekar K; Yang ES; Jacob R; Cardan R; Kim RY; Fiveash JB
    Radiat Oncol; 2014 Jun; 9():129. PubMed ID: 24893842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer.
    Ahmad Khalil D; Jazmati D; Geismar D; Wulff J; Bäumer C; Kramer PH; Steinmeier T; Schulze Schleitthoff S; Plaude S; Bischoff M; Tschirdewahn S; Hadaschik B; Timmermann B
    Radiat Oncol; 2022 Apr; 17(1):64. PubMed ID: 35365170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
    Cloitre M; Valerio M; Mampuya A; Rakauskas A; Berthold D; Tawadros T; Meuwly JY; Heym L; Duclos F; Vallet V; Zeverino M; Jichlinski P; Prior J; Roth B; Bourhis J; Herrera FG
    Br J Radiol; 2023 Apr; 96(1145):20220803. PubMed ID: 36745031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of a rectal hydrogel spacer on dosimetric and toxicity outcomes among patients undergoing combination therapy with external beam radiotherapy and low-dose-rate brachytherapy.
    Nehlsen AD; Sindhu KK; Moshier E; Sfakianos JP; Stock RG
    Brachytherapy; 2021; 20(2):296-301. PubMed ID: 33199175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients.
    Petersen SE; Thorsen LB; Hansen S; Petersen PM; Lindberg H; Moe M; Petersen JB; Muren LP; Høyer M; Bentzen L
    Acta Oncol; 2022 Feb; 61(2):179-184. PubMed ID: 34543143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes.
    Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
    Br J Radiol; 2021 Jan; 94(1117):20200848. PubMed ID: 33095659
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?
    Kupelian PA; Reddy CA; Carlson TP; Willoughby TR
    Cancer J; 2002; 8(1):62-6. PubMed ID: 11895204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
    Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
    Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.
    Norkus D; Karklelyte A; Engels B; Versmessen H; Griskevicius R; De Ridder M; Storme G; Aleknavicius E; Janulionis E; Valuckas KP
    Radiat Oncol; 2013 Sep; 8():206. PubMed ID: 24007322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study.
    Zilli T; Jorcano S; Rouzaud M; Dipasquale G; Nouet P; Toscas JI; Casanova N; Wang H; Escudé L; Mollà M; Linero D; Weber DC; Miralbell R
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):382-9. PubMed ID: 20884129
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: report on dosimetry aspects and acute toxicity in the Indian scenario.
    De S; Kannan V; Deshpande S; Anand V; Ghadi Y
    J Cancer Res Ther; 2010; 6(1):58-64. PubMed ID: 20479549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Use of hydrogel as spacer in Denovier's space: optimization of IMRT radiotherapy of localized prostate cancer].
    Klotz T; Mathers MJ; Lazar Y; Gagel B
    Urologe A; 2013 Dec; 52(12):1690-7. PubMed ID: 23942724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.
    Kupelian PA; Reddy CA; Klein EA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):988-93. PubMed ID: 11704322
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer.
    Al-Mamgani A; Heemsbergen WD; Peeters ST; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):685-91. PubMed ID: 18718725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.